Chiesi’s Raxone recommended for use within NHS Wales
Medicine recommended for the treatment of visual impairment in Leber’s Hereditary Optic Neuropathy
Read More
Tag: Raxone
Early access to Santhera’s DMD therapy Raxone extended in the UK
UK regulators have renewed the scientific opinion for Santhera’s Raxone, extending its availability to patients with Duchenne muscular dystrophy (DMD) through the Early Access to Medicines Scheme (EAMS) for another year.
Read More
Santhera’s Raxone fails in MS trial
Santhera has been hit with more bad news regarding its flagship mitochondrial disease therapy idebenone, after it failed to hit targets in a trial assessing its potential in multiple sclerosis.
Read More
EU advisors reject Santhera’s Raxone for muscular dystrophy
Santhera’s attempt to win approval for Raxone as a treatment for Duchenne Muscular Dystrophy (DMD) in Europe has hit a giant setback after receiving a negative opinion from European Medicines Agency advisors.
Read More
DMD patients in the UK win early access to Santhera’s Raxone
Santhera Pharmaceuticals’ Raxone has become the first drug for Duchenne Muscular Dystrophy (DMD) to join the UK’s Early Access to Medicines Scheme (EAMS).
Read More
Three new medicines cleared for use by NHS Scotland
The Scottish Medicines Consortium has endorsed three medicines for routine use by NHS Scotland, offering new options to treat a rare eye disease, lupus and infertility.
Read More
EU regulators review Santhera’s Raxone for Duchenne
European regulators have validated Santhera’s marketing application for Raxone as a treatment for certain patients with Duchenne muscular dystrophy.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
